A series of recent studies and clinical trials have indicated significant advancements in the use of CRISPR gene-editing technology for lowering cholesterol levels. Remarkably, a one-time gene-editing therapy has demonstrated the ability to cut harmful cholesterol levels, including LDL and triglycerides, by as much as half in early trials. This innovative approach targets specific genes, such as ANGPTL3 and APOC3, to potentially provide a permanent solution for individuals suffering from high cholesterol and dyslipidemia. Experts from institutions like the Cleveland Clinic are optimistic that these treatments could revolutionize cholesterol management, offering an effective alternative to traditional therapies.